VivoSeq
Other

Oxaliplatin

0

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Oxaliplatin is an early-stage landscape with 0 programs across 2 companies. The most active players are Traws Pharma, Inc., Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

85/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Traws Pharma, Inc.

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

18

clinical trials

Completed11 · 61%
Unknown status4 · 22%
Terminated1 · 6%
Recruiting1 · 6%
Withdrawn1 · 6%

Clinical Trials

Trial Activity

18 trials

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
Recruiting·UUniversity of Chicago·Phase 1·NCT04361708·54 enrolled
Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
Completed·TTraws Pharma, Inc.·Phase 1·NCT00861783·16 enrolled
Continuous Infusion of FU Combined With Epirubicin and Oxaliplatin in Patients With A/MGC
Completed·FFudan University·Phase 2·NCT00767377·163 enrolled
Long Term Effect of Oxaliplatin Treatment in Cancer Survivors
Completed·UUniversity Hospital, Clermont-Ferrand·N/A·NCT02970526·409 enrolled
Oxaliplatin in Cancer Patients With Impaired Kidney Function
Completed·National Cancer Institute (NCI)·Phase 1·NCT00001835·60 enrolled
Isolated Liver Perfusion With Oxaliplatin
Completed·—·Phase 1·NCT01042691·10 enrolled
A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan
Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 1·NCT02387138·24 enrolled
Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy
Completed·PPharmaEngine·Phase 1·NCT00940758·18 enrolled
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin
Completed·TTraws Pharma, Inc.·Phase 1·NCT00861328·18 enrolled
Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract
Completed·—·Phase 2·NCT03159143·22 enrolled
Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix
Completed·WWake Forest University Health Sciences·Phase 2·NCT01580410·136 enrolled
Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function
Completed·Sanofi logoSanofi·Phase 2·NCT00094965·43 enrolled
A Randomized Study to Establish the Efficacy of Oral Ice Exposure During Oxaliplatin Infusion in Preventing Oral Cold Sensitivity
Terminated·—·Phase 1·NCT03427021·65 enrolled
Hepatic Artery Infusion With Oxaliplatin
Withdrawn·MMedical College of Wisconsin·Phase 1/2·NCT00244348
A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC
Unknown status·—·Phase 4·NCT01997957·110 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)